New York, USA, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rich Insights into the Knee Osteoarthritis Clinical Trial Analysis Featuring 60+ Companies and Therapies | DelveInsight
The prevalence of Knee Osteoarthritis has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of osteoarthritis and the rise in the geriatric population. The Companies developing the potential therapies in the last stage of development include Bone Therapeutics, Biosplice Therapeutics, Levolta Pharmaceuticals, and several others.
DelveInsight’s 'Knee Osteoarthritis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline knee osteoarthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the knee osteoarthritis pipeline domain.
Key Takeaways from the Knee Osteoarthritis Pipeline Report
- DelveInsight’s knee osteoarthritis pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for knee osteoarthritis treatment.
- Key knee osteoarthritis companies such as Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, and others are evaluating new drugs for knee osteoarthritis to improve the treatment landscape.
- Promising knee osteoarthritis pipeline therapies in various stages of development include JTA-004, MM-II, Elixcyte, GXCPC1, PTP-001, Canakinumab, LNA043, PSC-01, CNTX-4975-05, StroMel, Lorecivivint, V120083, Cingal, PPV-06, FX201, TLC599, X0002, MEDI7352, Ampion, Resiniferatoxin, TPX 100, AMZ001, EP-104IAR, Adalimumab, Fasinumab, XT-150, YYD302, LRX712, Celltex- AdMSCs, Tanezumab, Lopain, PK101,DFV 890, Canakinumab, AS-902330, G001, ATB-346, Teriparatide, SL-1002, QUC 398, LEVI 04, LG00034053, JOINTSTEM, and others.
- In October 2022, Eupraxia Pharmaceuticals Inc. announced updates to its Phase II trial, which is evaluating EP-104IAR's efficacy and safety for the treatment of osteoarthritis ("OA") of the knee.Eupraxia announced that its ongoing Phase II study has successfully completed all DSMB reviews, with no drug-related Serious Adverse Events noted and a clean safety profile.
- In September 2022, KiOmed Pharma and Hansoh Pharmaceutical Group Company Limited announced a license agreement for the development and commercialization of KiOmedinevsOne, a carboxymethyl chitosan injection that has been launched in Europe for the treatment of knee osteoarthritis, in China’s mainland, Macau and Taiwan (the territory).Under the terms of the agreement, KiOmed will receive an upfront payment and will be eligible to receive development, regulatory and commercial milestones of up to € 66 million, as well as tiered royalties on future product sales.
- In September 2022, Pluri Inc. announced that a €7.5 million non-dilutive grant from the European Union’s Horizon Europe program had been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charité, Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize Pluri’s PLX-PAD cells in Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).
- In September 2022, Immunis Inc. formally signed a clinical trial agreement with the California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase I/IIa clinical trials. The trials will assess the safety and tolerability of Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.
- In June 2022, MiMedx Group, Inc. announced a collaboration agreement with Nordic Bioscience Clinical Development A/S (NBCD), a world-class Contract Research Organization (CRO) specializing in Osteoarthritis (OA) clinical trials.The Company plans to initiate its registrational Knee Osteoarthritis (KOA) clinical trial program later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints.
- In June 2022, Endo International plc announced that its subsidiary Endo Ventures Limited (EVL) had executed an agreement with Taiwan Liposome Company, Ltd. (TLC) to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase III development for the treatment of osteoarthritis knee pain.
Request a sample and discover the recent advances in knee osteoarthritis treatment drugs @Knee Osteoarthritis Pipeline Report
The knee osteoarthritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage knee osteoarthritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the knee osteoarthritis clinical trial landscape.
Knee Osteoarthritis Overview
Knee osteoarthritis, also known as the degenerative joint disease of the knee, is typically caused by wear and tear and progressive articular cartilage loss. It is most prevalent in the elderly. There are two types of knee osteoarthritis: primary and secondary. Age is the most common cause of knee osteoarthritis. Almost everyone will develop osteoarthritis at some point in their lives. Several factors, however, increase the risk of developing significant arthritis at a younger age.
The common knee osteoarthritis symptoms include swelling, feeling of warmth in the joint, stiffness in the knee, especially in the morning or after sitting for a while, decrease in knee mobility, and others. X-rays and MRI scans are widely used for knee osteoarthritis diagnosis.
Find out more about knee osteoarthritis treatment drugs @Drugs for Knee Osteoarthritis Treatment
A snapshot of the Knee Osteoarthritis Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| JTA-004 | Bone Therapeutics | Phase III | NA | Intra-articular |
| MM-II | Moebius Medical | Phase II | NA | Intra-articular |
| PTP-001 | Bioventus LLC | Phase II | Cell replacements | Intra-articular |
| Canakinumab | Novartis | Phase II | Interleukin 1 beta inhibitors | Intra-articular |
| Elixcyte | UnicoCell Biomed | Phase I/II | Cell replacements; Immunomodulators | Intra-articular |
| GXCPC1 | Gwo Xi Stem Cell Applied Technology | Phase I/II | Cell replacements | Intra-articular |
Learn more about the emerging knee osteoarthritis pipeline therapies @Knee Osteoarthritis Clinical Trials
Knee Osteoarthritis Therapeutics Assessment
The knee osteoarthritis pipeline report proffers an integral view of knee osteoarthritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Knee Osteoarthritis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Cell replacements, Immunomodulators, Interleukin 1 beta inhibitors, Cyclooxygenase inhibitors, Glucocorticoid receptor agonists, Cadherin 5 modulators; Fibrin inhibitors; Fibrin modulators; Integrin inhibitors, NLRP3 protein inhibitors.
- Key Knee Osteoarthritis Companies: Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Centrexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Eupraxia Pharmaceuticals, Celltex Therapeutics Corporation, Eli Lilly and Company, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, Biosplice Therapeutics, Jiangsu XinChen-Techfields Pharma Co., LTD., Teva Pharmaceutical Industries, Pfizer, Grünenthal GmbH, PMG Pharm Co., Ltd, Nordic Bioscience A/S, BUZZZ Pharmaceuticals Limited, Antibe Therapeutics, Saol Therapeutics Inc, LG Chem, and others.
- Key Knee Osteoarthritis Pipeline Therapies: JTA-004, MM-II, Elixcyte, GXCPC1, PTP-001, Canakinumab, LNA043, PSC-01, CNTX-4975-05, StroMel, Lorecivivint, V120083, Cingal, PPV-06, FX201, TLC599, X0002, MEDI7352, Ampion, Resiniferatoxin, TPX 100, AMZ001, EP-104IAR, Adalimumab, Fasinumab, XT-150, YYD302, LRX712, Celltex- AdMSCs, Tanezumab, Lopain, PK101,DFV 890, Canakinumab, AS-902330, G001, ATB-346, Teriparatide, SL-1002, QUC 398, LEVI 04, LG00034053, JOINTSTEM, and others.
Dive deep into rich insights for new drugs for knee osteoarthritis treatment, visit @Knee Osteoarthritis Medications
Table of Contents
| 1. | Knee Osteoarthritis Pipeline Report Introduction |
| 2. | Knee Osteoarthritis Pipeline Report Executive Summary |
| 3. | Knee Osteoarthritis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Knee Osteoarthritis Clinical Trial Therapeutics |
| 6. | Knee Osteoarthritis Pipeline: Late Stage Products (Pre-registration) |
| 7. | Knee Osteoarthritis Pipeline: Late Stage Products (Phase III) |
| 7.1 | JTA-004: Bone Therapeutics |
| 8. | Knee Osteoarthritis Pipeline: Mid Stage Products (Phase II) |
| 8.1 | MM-II: Moebius Medical |
| 9. | Knee Osteoarthritis Pipeline: Early Stage Products (Phase I) |
| 10. | Knee Osteoarthritis Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Knee Osteoarthritis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Knee Osteoarthritis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the knee osteoarthritis pipeline therapeutics, reach out @Knee Osteoarthritis Treatment Drugs
Related Reports
Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key knee osteoarthritis companies including Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., among others.
Osteoarthritis Epidemiology Forecast
Osteoarthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted osteoarthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteoarthritis companies including Arthrogen, GSK, Gilead Sciences, Medipost, Novartis, among others.
Osteoarthritis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoarthritis companies, including Arthrogen, GSK, Gilead Sciences, Medipost, Novartis, among others.
Erosive Hand Osteoarthritis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key erosive hand osteoarthritis companies, including Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, among others.
Erosive Hand Osteoarthritis Market
Erosive Hand Osteoarthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erosive hand osteoarthritis companies including Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
For more insights, browse through our latest blog on Knee Osteoarthritis Market Outlook
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
